FDA grants tentative approval to low-cost HIV shot
The potential rollout of a more affordable injection to help prevent HIV infection lifts hopes for reduced AIDS deaths in Africa.
The FDA has granted tentative approval to a generic HIV prevention shot, lenacapavir, which will be available at a significantly lower cost for 120 low- and middle-income countries. This development comes at a crucial time, as Western aid cuts have left many African nations struggling to fund HIV-prevention programs, potentially leading to hundreds of thousands of additional AIDS-related deaths. The affordable drug could play a pivotal role in ending the HIV epidemic, according to a global health advocate.
Brief written by urgent.news from Semafor's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
